Unity Biotechnology, Inc. (0YC0.L)
USD 1.02
(-1.45%)
USD 1.02
(-1.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -44.66 Million USD | 22.42% |
| 2022 | -57.57 Million USD | -1.6% |
| 2021 | -56.66 Million USD | 39.67% |
| 2020 | -93.93 Million USD | -4.77% |
| 2019 | -89.65 Million USD | -12.82% |
| 2018 | -79.46 Million USD | -74.23% |
| 2017 | -45.6 Million USD | -142.03% |
| 2016 | -18.84 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -8.09 Million USD | -2.82% |
| 2024 Q2 | -10.17 Million USD | -25.68% |
| 2024 Q3 | -6.6 Million USD | 35.14% |
| 2023 Q2 | -11.96 Million USD | -12.29% |
| 2023 Q4 | -7.87 Million USD | 47.24% |
| 2023 FY | -40.16 Million USD | 30.24% |
| 2023 Q1 | -10.65 Million USD | 23.45% |
| 2023 Q3 | -14.93 Million USD | -24.82% |
| 2022 Q4 | -13.91 Million USD | -5.99% |
| 2022 Q3 | -13.13 Million USD | -7.11% |
| 2022 FY | -57.57 Million USD | -1.6% |
| 2022 Q2 | -12.25 Million USD | 32.9% |
| 2022 Q1 | -18.26 Million USD | -84.55% |
| 2021 Q1 | -14.94 Million USD | 20.44% |
| 2021 FY | -56.66 Million USD | 39.67% |
| 2021 Q4 | -9.89 Million USD | 33.25% |
| 2021 Q3 | -14.82 Million USD | 12.76% |
| 2021 Q2 | -16.99 Million USD | -13.74% |
| 2020 Q1 | -27.15 Million USD | -17.61% |
| 2020 FY | -93.93 Million USD | -4.77% |
| 2020 Q4 | -18.78 Million USD | 23.78% |
| 2020 Q2 | -23.34 Million USD | 14.02% |
| 2020 Q3 | -24.64 Million USD | -5.54% |
| 2019 Q3 | -22.35 Million USD | 8.65% |
| 2019 Q1 | -19.73 Million USD | 13.46% |
| 2019 FY | -89.65 Million USD | -12.82% |
| 2019 Q4 | -23.09 Million USD | -3.29% |
| 2019 Q2 | -24.47 Million USD | -23.98% |
| 2018 Q2 | -20.79 Million USD | -26.19% |
| 2018 FY | -79.46 Million USD | -74.23% |
| 2018 Q1 | -16.48 Million USD | -28.91% |
| 2018 Q4 | -22.8 Million USD | -17.71% |
| 2018 Q3 | -19.37 Million USD | 6.83% |
| 2017 Q2 | -11.69 Million USD | -29.4% |
| 2017 FY | -45.6 Million USD | -142.03% |
| 2017 Q1 | -9.04 Million USD | 0.0% |
| 2017 Q4 | -12.78 Million USD | -5.82% |
| 2017 Q3 | -12.08 Million USD | -3.29% |
| 2016 FY | -18.84 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 73.598% |
| Dynavax Technologies Corporation | -37.02 Million USD | -20.63% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -747.732% |
| Perrigo Company plc | 151.9 Million USD | 129.406% |
| Illumina, Inc. | -1.06 Billion USD | 95.822% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.651% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 90.302% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.683% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 102.259% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 59.619% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 101.104% |
| Waters Corporation | 817.67 Million USD | 105.463% |
| Biogen Inc. | 1.29 Billion USD | 103.444% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 83.698% |
| Evolus, Inc. | -49.23 Million USD | 9.274% |
| Adicet Bio, Inc. | -152.03 Million USD | 70.621% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 63.236% |
| bluebird bio, Inc. | -244.26 Million USD | 81.713% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 71.287% |
| FibroGen, Inc. | -281.81 Million USD | 84.15% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 103.309% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 0.91% |
| Homology Medicines, Inc. | -48.25 Million USD | 7.435% |
| Geron Corporation | -193.94 Million USD | 76.969% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 84.17% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 39.224% |
| Myriad Genetics, Inc. | -123.7 Million USD | 63.891% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 55.699% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 91.332% |
| Zoetis Inc. | 3.06 Billion USD | 101.455% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 7.33% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 104.108% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 122.972% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 101.037% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -14.083% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 87.373% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 83.817% |
| Verastem, Inc. | -92.08 Million USD | 51.493% |
| Nektar Therapeutics | -137.42 Million USD | 67.497% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 80.732% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 54.12% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 83.322% |
| OPKO Health, Inc. | -157.02 Million USD | 71.553% |
| Exelixis, Inc. | 170.88 Million USD | 126.139% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 117.803% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 141.635% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 19.888% |
| uniQure N.V. | -282.87 Million USD | 84.209% |
| Imunon, Inc. | -21.03 Million USD | -112.392% |
| Blueprint Medicines Corporation | -486.27 Million USD | 90.814% |
| Insmed Incorporated | -709.62 Million USD | 93.706% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 113.232% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 88.59% |
| TG Therapeutics, Inc. | 20.63 Million USD | 316.483% |
| Incyte Corporation | 620.52 Million USD | 107.198% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 93.851% |